The client diagnosed with a traumatic brain injury (TBI) is experiencing increased intracranial pressure (ICP). The provider orders mannitol. For each intervention, specify if the intervention is indicated or not indicated for the clients care.

The safe administration of mannitol in a client with traumatic brain injury (TBI) is complicated by increased intracranial pressure (ICP). Mannitol is an osmotic diuretic used to reduce cerebral edema by drawing fluid from brain tissue into the intravascular space, promoting diuresis. Because it can significantly affect fluid balance, electrolytes, renal function, and cardiovascular status, close monitoring is essential. Nurses must understand administration precautions and physiologic monitoring to prevent complications such as hypovolemia, hypotension, and electrolyte imbalance. • Monitor cardiac rhythm during administration: Mannitol can cause rapid fluid shifts that may lead to electrolyte imbalances, particularly changes in sodium and potassium levels. These disturbances can predispose the client to dysrhythmias. Continuous or frequent cardiac monitoring helps detect early signs of cardiovascular instability. This is especially important in clients with TBI who may already have autonomic dysregulation. • Do not administer if blood pressure is less than 90/60: Mannitol increases intravascular fluid shifts and promotes diuresis, which can worsen hypotension. If the client is already hypotensive, administration may reduce cerebral perfusion pressure further, worsening brain injury. Maintaining adequate cerebral perfusion is critical in TBI management. Therefore, low blood pressure is a contraindication to safe administration. • Use a filter needle when administering the prescription: Mannitol can crystallize at room temperature, especially if improperly stored or cooled. Using a filter needle ensures that any crystals or particulate matter are not administered intravenously. This prevents embolic complications and ensures safe delivery of the medication. • Monitor serum osmolarity during administration: Mannitol increases serum osmolarity by drawing fluid from intracellular to intravascular spaces. Monitoring osmolarity helps prevent complications such as renal impairment and excessive fluid shifts. Elevated serum osmolarity can indicate risk for kidney injury or fluid overload. Maintaining safe osmolar levels is essential in preventing further neurologic deterioration. • Assess IM injection site for phlebitis: Mannitol is administered intravenously, not intramuscularly, so IM site assessment is not relevant. Phlebitis refers to inflammation of a vein, typically associated with IV therapy, not IM injections. Therefore, assessing an IM site has no clinical relevance to this medication. The correct focus should be on IV access site integrity instead.